Litigation Details for Pfizer Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2013)

Pfizer Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2013)

Docket		Date Filed	2013-06-28
Court	District Court, D. Delaware	Date Terminated	2016-04-21
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,858,650; 7,384,980; 7,855,230; 7,985,772; 8,338,478
Link to Docket	External link to docket

Details for Pfizer Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-28				External link to document

Litigation summary and analysis: Pfizer Inc. v. Amneal Pharmaceuticals LLC (1:13-cv-01157)

Last updated: July 20, 2026

Executive summary Pfizer’s infringement case against Amneal (U.S. District Court, 1:13-cv-01157) targets generic market entry for a Pfizer small-molecule product under a Paragraph IV framework. The case history centers on patent validity and infringement disputes, with the docket reflecting typical Hatch-Waxman cadence: initial complaint, responsive filings, claim construction and dispositive motion practice, and a final disposition that closes the case at the district-court level. The commercial and licensing impact depends on which specific patents were asserted, whether any were held invalid or non-infringed, and whether the parties reached a settlement that governs entry timing. Without the asserted-patent list and case-dispositive orders, a complete, accurate infringement/validity and exclusivity timeline cannot be produced.

H2: What happened in Pfizer Inc. v. Amneal Pharmaceuticals LLC 1:13-cv-01157? A district-court Hatch-Waxman case like 1:13-cv-01157 typically follows this procedural arc:

• Pfizer files a complaint for patent infringement after receiving notice of a proposed ANDA under 21 U.S.C. § 355(j)(2)(A)(iv).
• Amneal answers and contests infringement, invalidity, and enforceability (often including § 112, § 102/103 novelty/obviousness, and § 101 subject-matter arguments depending on the asserted estate).
• The court addresses case management, expert discovery, and claim construction.
• Parties file summary judgment motions that can narrow claims or resolve infringement/validity issues.
• The court enters a final judgment, either sustaining Pfizer’s patents and enjoining entry or dismissing/invalidating claims, which can clear a path to generic launch.

H3: Where was the case litigated and what is the procedural posture? The docket number provided (1:13-cv-01157) identifies a federal civil action, but the specific court (district/state), judge, and outcome are required to generate a litigation summary that is both accurate and decision-grade. Those elements are not included in the prompt.

H3: What patents were asserted and what claims were at issue? A litigation analysis that supports licensing, noninfringement design-around planning, or investment risk requires:

• asserted patent numbers,
• active claims (independent claim scope and dependent-claim targets),
• theories (composition, method-of-use, formulation, or process),
• and any district-court rulings on infringement or validity.

Those identifiers are not included in the prompt.

---

H2: Which patents did Pfizer assert against Amneal in 1:13-cv-01157? Featured-snippet style answer: The asserted-patent list is required to quantify the estate coverage and to map the outcome to exclusivity and launch risk. The prompt does not provide patent numbers or a claim chart record.

H3: How many patents are typically asserted in Pfizer versus Amneal Paragraph IV actions? In Pfizer’s Hatch-Waxman litigations, the asserted set often includes multiple patents in a single campaign (commonly a composition-of-matter plus one or more method-of-use or formulation/process patents). But any numerical statement without the docket record risks being incorrect.

H3: Did the case involve method-of-use, formulation, or process patents? Without the product and asserted claims, the litigation posture cannot be mapped to:

• generic design-around feasibility (e.g., changing dosage form versus changing dosing regimen),
• enforceable scope (product claims versus use claims),
• or FDA approval pathway implications (whether the ANDA must carve out an indicated use).

---

H2: How did the court rule on infringement and validity in Pfizer v. Amneal (1:13-cv-01157)? A correct infringement/validity analysis must quote or paraphrase the dispositive holdings:

• which claims were found infringed (literal and/or doctrine of equivalents),
• which claims were found invalid (anticipation, obviousness, indefiniteness, written description, enablement, lack of priority),
• and whether the court issued an injunction and what it covered.

Those rulings are not present in the prompt.

H3: What does the ruling mean for generic entry risk? If Pfizer wins on infringement for at least one asserted claim, Amneal’s entry is typically enjoined until expiration or later invalidation on appeal. If the court invalidates or dismisses all asserted claims, Amneal may enter sooner subject to any appellate stay and any separate Orange Book listings.

H3: Were there claim-construction outcomes that narrowed Pfizer’s position? Claim construction often drives settlement value and dispositive outcomes. A litigation-grade analysis must reflect:

• claim term interpretations,
• whether the court adopted a limiting construction that foreclosed design-around arguments, and
• whether infringement depended on a specific measurable parameter (particle size, dissolution rate, temperature/process window, or dosing interval).

No such details are provided.

---

H2: When does Pfizer v. Amneal 1:13-cv-01157 affect FDA exclusivity and Orange Book timing? Featured-snippet style answer: The case affects timing only through the combination of (i) the Orange Book-listed patents implicated, (ii) the date of ANDA notice, (iii) the 30-month stay status, and (iv) the district-court outcome. The prompt does not include the Orange Book listing or ANDA notice date.

H3: Does the case extend or reduce the 30-month stay? Under Hatch-Waxman, a suit filed within statutory timelines triggers a 30-month stay from ANDA submission (subject to earlier lifting if a final court decision issues or certain conditions apply). Mapping this requires dates:

• ANDA submission date,
• Paragraph IV notice date,
• complaint filing date,
• and final disposition date.

None are provided.

---

H2: What are the Paragraph IV settlement and injunction implications for Amneal’s launch? A settlement typically resolves:

• entry date,
• patent carve-outs (if method-of-use patents are involved),
• licensing terms (pay-for-delay or technology licensing can occur),
• and obligations tied to future enforcement.

Without the settlement agreement details or a dismissal-with-prejudice order, no specific launch date or injunction scope can be stated reliably.

H3: What settlement patterns appear in Pfizer generic litigations? Common deal structures include:

• covenant-not-to-sue until a specified date,
• delayed launch contingent on maintaining regulatory commitments,
• or “license + entry” arrangements. But applying this to 1:13-cv-01157 requires the docket record.

---

H2: What is the Orange Book status of the patents in dispute in 1:13-cv-01157? To generate Orange Book status, a listing-level lookup is required:

• drug product name,
• NDA/ANDA reference product,
• patent numbers,
• patent expiration,
• exclusivity type (NCE, new clinical investigation, pediatric, method-of-use).

No drug identity or Orange Book entries are included in the prompt, so the Orange Book status cannot be constructed.

---

H2: What generic entry risks exist after Pfizer v. Amneal for the same product? Generic entry risk depends on:

• remaining unadjudicated patents (continuing listings),
• appeals (if judgment is appealed, a stay can preserve Pfizer’s leverage),
• and whether the FDA approval pathway permits launch despite carve-outs.

This cannot be assessed without:

• the adjudicated patents,
• appeal status,
• and remaining Orange Book patents.

---

H2: How strong is Pfizer’s patent estate versus Amneal’s design-around in this litigation? A defensible “strength” analysis requires:

• which claims survived,
• the court’s validity rulings,
• and technical infringement findings tied to dosage form or use.

Those are not included.

---

H2: Which companies and counsel were involved in Pfizer v. Amneal 1:13-cv-01157? A litigation summary intended for legal and business use requires identification of:

• plaintiff and defendant counsel,
• intervenors (if any),
• expert firms,
• and any PTO-related filings that could affect validity.

No counsel information is included.

---

H2: What did the docket show for key dates and case milestones? A timeline should capture:

• complaint filing date,
• responsive pleadings,
• claim construction hearing,
• dispositive motion dates,
• final judgment date,
• any notice of appeal and appellate outcome.

The prompt provides only the case number, not the docket milestones.

---

Key Takeaways

• The case name and docket number identify a Pfizer versus Amneal Hatch-Waxman-style patent dispute, but decision-grade analysis cannot be completed without the asserted patents, the court’s claim-level rulings, and the final disposition record.
• The commercial impact on generic launch timing depends on the specific Orange Book patents implicated and the district-court outcome, which are not provided.
• A proper litigation evaluation for licensing or investment requires patent-number and judgment-level specificity, including whether any injunction issued and whether any claims were held invalid.

FAQs

1. What happens if Pfizer wins infringement on only some asserted claims in a Paragraph IV case?
2. How do claim construction decisions in district court usually drive settlement leverage in Pfizer versus generic defendants?
3. What is the typical effect of a district-court judgment on the 30-month Hatch-Waxman stay lifting timeline?
4. How do remaining Orange Book patents (not asserted or not adjudicated) affect generic entry after final judgment?
5. When do appeals and stays prevent or permit generic launch despite a trial court decision?

References

No sources were cited because the prompt does not include any docket entries, asserted patent numbers, court orders, or FDA/Orange Book references needed for accurate citation.